Welcome!

News Feed Item

Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Protease, Lipase, Polymerases & Nucleases), Application (Pharmaceutical, Research & biotechnology, Diagnostic, Bio-Catalyst) & Geography - Global Trends & Forecasts to

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Protease, Lipase, Polymerases & Nucleases), Application (Pharmaceutical, Research & biotechnology, Diagnostic, Bio-Catalyst) & Geography - Global Trends & Forecasts to

http://www.reportlinker.com/p02116957/Specialty-Enzymes-Market-by-Source-Microorganism-Plant-Animal-Type-Carbohydrases-Protease-Lipase-Polymerases--Nucleases-Application-Pharmaceutical-Research--biotechnology-Diagnostic-Bio-Catalyst--Geography---Global-Trends--Forecasts-to.html

Specialty enzymes are natural proteins produced from micro organisms, plants and animals. An enzyme serves as catalysts for the chemical process that include the production of pharmaceuticals, diagnostics, research & biotechnology, and biocatalytic solutions. Enzymes increase reaction rates by decreasing the amount of energy required to form a complex of reactants that is competent to produce reaction products. Specialty enzymes according to their type are classified as carbohydrases, proteases, polymerases and nucleases, lipases, and others.

Specialty enzymes report covers analysis of the market structure by identifying various sub-segments of the global specialty enzymes market, Revenue forecasts of the global specialty enzymes markets and its various sub-markets/micro-markets with respect to four main regions- North America, Europe, Asia-Pacific, and Rest of the World (RoW). Major trends, drivers, and restraints of the global specialty enzymes market are identified and explained in detail.

The specialty enzyme markets include pharmaceutical, research and biotechnology, diagnostics and biocatalysts. Pharmaceutical manufacturers are witnessing increased awareness in incorporating biocatalysis into manufacturing processes. Enzymes are particularly useful to generate isomerically pure pharmaceuticals and fine chemicals In spite of numerous advantages of biocatalysis, manufacturers have been slow to adopt industrial-scale enzymatic approaches.

Specialty enzyme usage in the pharmaceutical industry is mainly for drug manufacture, disease diagnostics, or as therapy. Increasing implication of enzymes in therapies for diseases such as cancer, cardiovascular diseases, lysosomal storage disorders, pain and inflammation management, among others, is a tidal force that fuels market demand. Enzyme demand in the research and biotechnology end-market would benefit from the fall in DNA sequencing costs and the increase of new sequencing techniques. The vast majority of enzymes used in research and biotechnology, which spans over 80%of the demand, are devoted to DNA amplification and sequencing. This segment is led by DNA polymerases, which has experienced strong growth as new DNA sequencing techniques have been developed in recent years and the cost of DNA sequencing has dropped dramatically. The number of investigations is expected to increase, creating a strong business case for specialty enzymes

The North America is the largest market for specialty enzymes followed by Europe and Asia-Pacific respectively. Pharmaceuticals and diagnostics enzymes are expected to contribute more market share by 2018. Europe was the second largest market for the production and consumption of specialty enzymes.

The rising middle class population, increase in per capita income, rising healthcare expenditure, increasing prevalence of diseases, increasing affordability on the part of consumers, and rapid growth technologies find growing opportunities in Asia-Pacific and ROW. Countries such as China, India, South Africa, and Brazil have tremendous scope for the specialty enzyme market. The development of novel and superior performing products and rapid growing technology would enable specialty enzyme manufacturers to explore vast untapped potential of the emerging markets in Asia-Pacific and Latin American regions.

1 INTRODUCTION 14

1.1 KEY TAKE-AWAYS 14
1.2 REPORT DESCRIPTION 15
1.3 STAKEHOLDERS 16
1.4 RESEARCH METHDOLOGY 16
1.4.1 MARKETS COVERED 17
1.4.2 MARKETS SIZE 18
1.4.3 ASSUMPTIONS MADE FOR THE REPORT 18
1.4.4 KEY DATA POINTS VALIDATED FROM PRIMARY & SECONDARY SOURCES 19
1.4.5 KEY QUESTIONS ANSWERED 19

2 EXECUTIVE SUMMARY 20

3 PREMIUM INSIGHTS 22

3.1 NORTH AMERICA: THE PRODIGIOUS MARKET 22
3.2 THE NEXT FRONTIERS: BRAZIL, INDIA,& CHINA 23
3.3 PHARMACEUTICALS & DIAGNOSTICS-THE BIGGEST MARKET DRIVERS 24
3.4 MICRO-ORGANISMS- DOMINATING SOURCE OF ENZYMES 25

4 MARKET OVERVIEW 26

4.1 INTRODUCTION 27
4.2 DRIVERS 29
4.2.1 THE AGING APPLICATION FUELS THE PHARMACEUTICAL DIGNOSTIC ENZYMES DEMAND 30
4.2.2 ROBUST INVESTMENTS IN THE BIOTECH SECTOR PULLS THE DEMAND FOR ENZYMES 31
4.2.3 RAPID GROWTH IN THE PHARMACEUTICAL INDUSTRY 32
4.2.4 ADVANCEMENT IN ENZYME ENGINEERING & GREEN CHEMISTRY 33
4.3 OPPORTUNITIES 34
4.3.1 EMERGING REGIONAL MARKET 34
4.3.2 THE RISING CLINICAL IN VITRO DIAGNOSTICS INDUSTRY 34
4.3.3 RESTRAINS 35
4.3.4 RESTRICTED TEMPERATURE & THE PH OPERATIONAL RANGE OF ENZYMES 35
4.3.4.1 Legal & Ethical Issues 36
4.4 WINNING IMPERATIVE-GLOBAL PHARMACEUTICAL INDUSTRY OUTLOOK 37
4.5 PORTER'S FIVE FORCES ANALYSIS 39
4.5.1 DEGREE OF COMPETITION 40
4.5.2 BARGAINING POWER OF SUPPLIERS 40
4.5.3 BARGAINING POWER OF BUYERS 40
4.5.4 THREAT OF SUBSTITUTES 41
4.5.5 THREAT OF NEW ENTRANTS 41
4.6 MARKET SHARE ANALYSIS 42

5 GLOBAL SPECIALTY ENZYMES MARKET, BY SOURCE 44

5.1 INTRODUCTION 45
5.2 MICRO-ORGANISMS 47
5.3 PLANTS 49
5.4 ANIMALS 51

6 SPECIALTY ENZYME MARKET, BY TYPE 53

6.1 INTRODUCTION 54
6.2 CARBOHYDRASES 56
6.2.1 AMYLASES 57
6.2.2 CELLULASES 57
6.2.3 OTHER CARBOHYDRASES 58
6.3 PROTEASES 58
6.4 POLYMERASES &NUCLEASES 61
6.5 LIPASES 62
6.6 OTHERS 62
6.7 SPECIALTY ENZYMES USED IN PHARMACEUTICALS 64
6.8 SPECIALTY ENZYMES USED IN DIAGNOSTICS 65
6.9 SPECIALTY ENZYMES USED FOR RESEARCH & BIOTECHNOLOGY 66

7 SPECIALTY ENZYME MARKET, BY APPLICATION 67

7.1 INTRODUCTION 68
7.2 PHARMACEUTICALS 71
7.2.1 ENZYME REPLACEMENT THERAPY 73
7.2.2 THROMBOLYTIC ENZYMES 73
7.2.3 DIGESTIVE ENZYMES 73
7.3 RESEARCH & BIOTECHNOLOGY 74
7.4 DIAGNOSTIC 76
7.5 BIO-CATALYST 78

8 SPECIALTY ENZYMES MARKET, BY GEOGRAPHY 80

8.1 INTRODUCTION 81
8.2 NORTH AMERICA: SPECIALTY ENZYMES MARKET 82
8.2.1 U.S.: SPECIALTY ENZYME MARKET 85
8.2.2 CANADA: SPECIALTY ENZYME MARKET 87
8.2.3 MEXICO: SPECIALTYENZYMES MARKET 89
8.3 EUROPE: SPECIALTY ENZYME MARKET 91
8.3.1 GERMANY: SPECIALTY ENZYMES MARKET 94
8.3.2 U.K.: SPECIALTY ENZYMES MARKET 96
8.3.3 FRANCE: SPECIALTY ENZYMES MARKET 98
8.4 ASIA PACIFIC: SPECIALTY ENZYMES MARKET 101
8.4.1 CHINA:SPECIALTY ENZYME MARKET 104
8.4.2 INDIA:SPECIALTY ENZYME MARKET 106
8.4.3 JAPAN:SPECIALTY ENZYME MARKET 108
8.5 ROW : SPECIALTY ENZYMES MARKET 110
8.5.1 SOUTH AFRICA: SPECIALTY ENZYMES MARKET 113

9 COMPETITIVE LANDSCAPE 118

9.1 INTRODUCTION 119
9.2 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS: MOST PREFERRED STRATEGIC APPROACH 119
9.2.1 MAXIMUM DEVELOPMENTS IN 2012 121
9.2.2 SANOFI & LIFE TECHNOLOGIES -THE MOST ACTIVE PLAYERS 122
9.3 ACQUISTIONS 123
9.4 NEW PRODUCTS LAUNCH & PRODUCT DEVELOPMENTS 126
9.5 AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS 127
9.6 EXPANSIONS & OTHER DEVELOPMENTS 131

10 COMPANY PROFILES 134 (Overview, Financials, Products & Services, Strategy, and Developments)*

10.1 BASF 134
10.2 AMANO ENZYME INC. 139
10.3 CODEXIS INC. 142
10.4 SANOFI S.A. 145
10.5 ROCHE HOLDING AG. 151
10.6 ADVANCED ENZYME TECHNOLOGY LTD. 155
10.7 LIFE TECHNOLOGIES 158
10.8 NAGASE & CO. LTD. 163
10.9 BBI ENZYMES LTD. 167
10.10 AFFYMETRIX INC. 169
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 GLOBAL POPULATION AGED 60 OR OVER, 2012-2050 30
TABLE 2 GROWTH IN ESTABLISHED BIOTECHNOLOGY CENTRES,
2011-2012 ($BILLION) 31
TABLE 3 OUTLOOK OF THE GLOBAL USE OF MEDICINES, BY GEOGRAPHY,
2007-2016($ BILLION) 32
TABLE 4 BIO-CATALYST ALIGNMENT WITH GREEN CHEMISTRY 33
TABLE 5 GLOBAL PHARMACEUTICAL DEMAND, BY THERAPEUTIC SEGMENT, 2000-2020 ($BILLION) 38
TABLE 6 GLOBAL SPECIALTY ENZYMES MARKET REVENUE, BY SOURCE,
2011-2018 ($MILLION) 46
TABLE 7 MICRO-ORGANISM-BASED SPECIALTY ENZYMES & THEIR APPLICATIONS 47
TABLE 8 MICRO-ORGANISM-BASED SPECIALTY ENZYMES MARKET,
BY GEOGRAPHY, 2011-2018 ($MILLION) 48

TABLE 9 PLANT-BASED SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($MILLION) 50
TABLE 10 ANIMAL BASED SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($ MILLION) 52
TABLE 11 GLOBAL SPECIALTY ENZYMES MARKET VALUE, BY TYPE,
2011–2018 ($MILLION) 55
TABLE 12 CARBOHYDRASES ENZYMES MARKET VALUE, BY GEOGRAPHY,
2011–2018($MILLION) 56
TABLE 13 TYPE OF PROTEASE &THEIR SPECIFICITY 59
TABLE 14 PROTEASES ENZYMES MARKET VALUE,BY GEOGRAPHY,
2011–2018($MILLION) 60
TABLE 15 POLYMERASES & NUCLEASES ENZYMES MARKET VALUE,
BY GEOGRAPHY,2011–2018($MILLION) 61
TABLE 16 OTHERS ENZYMES MARKET VALUE,BY GEOGRAPHY,
2011–2018($MILLION) 63
TABLE 17 GLOBAL PHARMACEUTICAL SPECIALTY ENZYMES MARKET VALUE,
BY TYPE,2011–2018($MILLION) 64
TABLE 18 GLOBAL DIAGNOSTIC SPECIALTY ENZYMES MARKET VALUE,BY TYPE, 2011–2018 ($MILLION) 65
TABLE 19 GLOBAL RESEARCH & BIOTECHNOLOGY SPECIALTY ENZYMES MARKET VALUE, BY TYPE, 2011–2018 ($MILLION) 66

TABLE 20 SPECIALTY ENZYMES MARKET, BY APPLICATION,
2011-2018 ($MILLION) 69
TABLE 21 PHARMACEUTICALS: SPECIALTY ENZYMES MARKET, BY GEOGRAPHY, 2011-2018 ($MILLION) 71
TABLE 22 PHARMACEUTICALS: GLOBAL SPECIALTY ENZYMES MARKET,
BY APPLICATION, 2011-2018 ($MILLION) 72
TABLE 23 RESEARCH & BIOTECHNOLOGY: SPECIALTY ENZYMES MARKET,
BY GEOGRAPHY, 2011-2018 ($MILLION) 75
TABLE 24 DIAGNOSTICS: SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($MILLION) 77
TABLE 25 BIO-CATALYSTS: SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($MILLION) 78
TABLE 26 NORTH AMERICA: SPECIALTY ENZYME MARKET, BY COUNTRY,
2011-2018 ($MILLION) 82
TABLE 27 NORTH AMERICA: SPECIALTY ENZYME MARKET, BY APPLICATION, 2011-2018 ($MILLION) 83
TABLE 28 NORTH AMERICA:SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 84
TABLE 29 U.S.: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 85
TABLE 30 U.S.: SPECIALTY ENZYME MARKET, BY SOURCE, 2011-2018 ($MILLION) 86
TABLE 31 CANADA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 87

TABLE 32 CANADA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 88
TABLE 33 MEXICO: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 89
TABLE 34 MEXICO: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 90
TABLE 35 EUROPE: SPECIALTY ENZYMES MARKET, BY COUNTRY,
2011-2018 ($MILLION) 91
TABLE 36 EUROPE: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 92
TABLE 37 EUROPE:SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 93
TABLE 38 GERMANY: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 94
TABLE 39 GERMANY: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 95
TABLE 40 U.K.: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 96
TABLE 41 U.K.: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 97

TABLE 42 FRANCE: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 98
TABLE 43 FRANCE: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 99
TABLE 44 OTHERS EU: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 100
TABLE 45 ASIA-PACIFIC: SPECIALTY ENZYMES MARKET, BY COUNTRY,
2011-2018 ($MILLION) 101
TABLE 46 ASIA-PACIFIC: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 102
TABLE 47 ASIA-PACIFIC: SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 103
TABLE 48 CHINA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 104
TABLE 49 CHINA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018($MILLION) 105
TABLE 50 INDIA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 106

TABLE 51 INDIA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 107
TABLE 52 JAPAN: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 108
TABLE 53 OTHERS APAC: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 109
TABLE 54 ROW: SPECIALTY ENZYMES MARKET, BY COUNTRY,
2011-2018 ($MILLION) 110
TABLE 55 ROW: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 111
TABLE 56 ROW: SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 112
TABLE 57 SOUTH AFRICA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 113
TABLE 58 SOUTH AFRICA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 114
TABLE 59 BRAZIL: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 115
TABLE 60 BRAZIL: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 116
TABLE 61 OTHERS ROW: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 117

TABLE 62 MERGERS & ACQUISITIONS, 2009–2013 123
TABLE 63 NEW PRODUCTS LAUNCH & PRODUCT DEVELOPMENTS, 2009–2013 126
TABLE 64 AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS, 2009–2013 127
TABLE 65 EXPANSIONS & OTHER DEVELOPMENTS, 2009–2013 131
TABLE 66 BASF: PRODUCTS & THEIR DESCRIPTION 135
TABLE 67 AMANO ENZYME: PRODUCTS & THEIR APPLICATIONS 140
TABLE 68 SOUFFLET GROUP: PRODUCTS & THEIR DESCRIPTION 143
TABLE 69 SANOFI: PRODUCTS & THEIR DESCRIPTION 146
TABLE 70 ROCHE: PRODUCTS & THEIR DESCRIPTION 152
TABLE 71 ADVANCED ENZYMES TECHNOLOGY LTD.: PRODUCTS & THEIR DESCRIPTION 156
TABLE 72 LIFE TECHNOLOGIES LTD.: PRODUCTS & THEIR DESCRIPTION 159
TABLE 73 NAGASE & CO. LTD.: PRODUCTS & THEIR DESCRIPTION 164
TABLE 74 BBI ENZYMES LTD.: PRODUCTS & THEIR DESCRIPTION 168
TABLE 75 AFFYMETRIX: PRODUCTS & THEIR DESCRIPTION 170

LIST OF FIGURES

FIGURE 1 GLOBAL SPECIALTY ENZYMES MARKET,BY GEOGRAPHY, 2012 20
FIGURE 2 GLOBAL SPECIALTY ENZYME MARKET VALUE, BY GEOGRAPHY,
2012-2018 ($MILLION) 22
FIGURE 3 SPECIALTY ENZYME MARKET VALUE, BY COUNTRY,
2012 VS 2018($MILLION) 23
FIGURE 4 SPECIALTY ENZYME MARKET, BY APPLICATION, 2012-2018 ($MILLION) 24
FIGURE 5 SPECIALTY ENZYME MARKET VALUE, BY TYPE, 2012-2018 ($MILLION) 25
FIGURE 6 SPECIALTY ENZYME MARKET SEGMENTATION 28
FIGURE 7 DRIVERS & RESTRAINTS FOR SPECIALTY ENZYMES 29
FIGURE 8 EFFECT OF TEMPERATURE ON THE RATE OF AN ENZYME-CATALYZED REACTION 35
FIGURE 9 EFFECT OF PH ON THE RATE OF AN ENZYME-CATALYZED REACTION 36
FIGURE 10 PORTER'S FIVE FORCES ANALYSIS 39
FIGURE 11 SPECIALTY ENZYMES: GLOBAL MARKET SHARE ANALYSIS,
BY COMPANY, 2012 42
FIGURE 12 SPECIALTY ENZYMES, BY APPLICATION 68
FIGURE 13 SPECIALTY ENZYMES MARKET SHARE, BY APPLICATION, 2012 70
FIGURE 14 SPECIALITY ENZYMES MARKET SHARE, BY GROWTH STRATEGY,
2010–2013 120
FIGURE 15 SPECIALITY ENZYMES MARKET DEVELOPMENTS, 2009–2013 121
FIGURE 16 SPECIALITY ENZYMES DEVELOPMENT SHARE, BY COMPANY, 2009-2013 122
FIGURE 17 BASF: SWOT ANALYSIS 138
FIGURE 18 SANOFI: SWOT ANALYSIS 150
FIGURE 19 ROCHE: SWOT ANALYSIS 154
FIGURE 20 LIFE TECHNOLOGIES: SWOT ANALYSIS 162
FIGURE 21 NAGASE: SWOT ANALYSIS 166

To order this report: Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Protease, Lipase, Polymerases & Nucleases), Application (Pharmaceutical, Research & biotechnology, Diagnostic, Bio-Catalyst) & Geography - Global Trends & Forecasts to
http://www.reportlinker.com/p02116957/Specialty-Enzymes-Market-by-Source-Microorganism-Plant-Animal-Type-Carbohydrases-Protease-Lipase-Polymerases--Nucleases-Application-Pharmaceutical-Research--biotechnology-Diagnostic-Bio-Catalyst--Geography---Global-Trends--Forecasts-to.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"NetApp is known as a data management leader but we do a lot more than just data management on-prem with the data centers of our customers. We're also big in the hybrid cloud," explained Wes Talbert, Principal Architect at NetApp, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, introduced two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a multip...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...